---
title: "Zydus 的药物 Desidustat 用于治疗肾性贫血已获得中国监管机构的批准"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/279125432.md"
description: "Zydus Lifesciences 已获得中国国家药品监督管理局对其药物 Desidustat 的批准，该药物用于治疗慢性肾病（CKD）患者的肾性贫血。该药物已授权给中国医疗系统控股的子公司 CMS International Development and Management Ltd。Zydus 旨在改善患者的治疗效果，并扩大在大中华区的 CKD 治疗覆盖面，该地区有超过 1.2 亿 CKD 患者。Desidustat 在印度以 Oxemia 的品牌销售，自 2022 年上市以来，已有超过 100,000 名患者接受治疗"
datetime: "2026-03-14T06:01:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279125432.md)
  - [en](https://longbridge.com/en/news/279125432.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279125432.md)
---

# Zydus 的药物 Desidustat 用于治疗肾性贫血已获得中国监管机构的批准

Zydus Lifesciences on Saturday said its innovative drug has received approval from China's National Medical Products Administration (NMPA) for its drug Desidustat tablets used for treating renal anaemia.

The company has licensed its Desidustat tablets to a subsidiary of China Medical System Holdings Ltd.

CMS International Development and Management Ltd, a wholly-owned subsidiary of CMS, had obtained an exclusive license for the drug from Zydus in 2020.

Desidustat tablets are administered orally for treating anaemia in Chronic Kidney Disease (CKD) patients. CKD involves the gradual loss of kidney function and eventually leads to kidney failure.

"We are encouraged by the NMPA's approval for marketing the drug in China. Our life-changing discoveries are driven by a commitment to improving patient outcomes and enabling healthier, more fulfilled lives, globally," Zydus Lifesciences MD Sharvil P Patel said in a statement.

The company is happy to partner with CMS and is confident that this will expand access to patients suffering from Chronic Kidney Disease across Greater China, he added.

Desidustat is discovered, developed and marketed by Zydus in India under the brand name Oxemia. More than 1 lakh CKD patients in India have been successfully treated with Oxemia since its launch in 2022, the drug firm stated.

There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China.

### 相关股票

- [8A8.SG](https://longbridge.com/zh-CN/quote/8A8.SG.md)

## 相关资讯与研究

- [强生重症肌无力治疗新药获国家药监局批准上市](https://longbridge.com/zh-CN/news/287196062.md)
- [FDA 药物中心主任在局长离任后被解职](https://longbridge.com/zh-CN/news/286647408.md)
- [【IPO 速递】药物输送龙头安得医疗闯港股，收入两年连降、连续三年分红](https://longbridge.com/zh-CN/news/286726988.md)
- [阿斯利康高血压药物获美国批准](https://longbridge.com/zh-CN/news/286741013.md)
- [默沙东 ADC 药物达 III 期主要终点](https://longbridge.com/zh-CN/news/286929703.md)